Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Gains from Investment Securities (2019 - 2025)

Harmony Biosciences Holdings' Gains from Investment Securities history spans 7 years, with the latest figure at $213758.0 for Q2 2025.

  • For Q2 2025, Gains from Investment Securities fell 99.49% year-over-year to $213758.0; the TTM value through Jun 2025 reached $213758.0, down 99.53%, while the annual FY2024 figure was $7.2 million, 13.31% up from the prior year.
  • Gains from Investment Securities for Q2 2025 was $213758.0 at Harmony Biosciences Holdings, down from $1.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $41.6 million in Q2 2024 and bottomed at -$41.8 million in Q3 2024.
  • The 5-year median for Gains from Investment Securities is $1.2 million (2021), against an average of $1.8 million.
  • The largest annual shift saw Gains from Investment Securities surged 1288.99% in 2021 before it plummeted 99.49% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $2.0 million in 2021, then surged by 229.81% to $6.5 million in 2022, then tumbled by 80.59% to $1.3 million in 2023, then surged by 46.01% to $1.8 million in 2024, then crashed by 88.33% to $213758.0 in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Gains from Investment Securities are $213758.0 (Q2 2025), $1.0 million (Q1 2025), and $1.8 million (Q4 2024).